AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 151 min read

BTIG maintains Buy rating on Verastem, $24 price target

BTIG maintained a Buy rating on Verastem with a $24 price target, implying a 211.3% upside. Analysts cited strong clinical efficacy of VS-7375, including a 41% cORR and 67% six-month PFS, and a favorable safety profile.

Original reporting
tradingview.com
Published Oct 15, 2026, 9:53 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 9:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BTIG maintains Buy rating on Verastem, $24 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The analyst upgrade and higher target reflect confidence that the trial results will improve the company's valuation.

02

Market read

New positive trial data for a small‑cap biotech can trigger a sharp price move, offering a short‑term trading opportunity.

03

What to watch

Potential competition and the need for larger Phase 3 data could temper upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

BTIG maintains a Buy rating on Verastem (VRSN) with a $24 price target, citing new clinical efficacy and safety data for its candidate VS‑7375 in pancreatic cancer.

Market effects

Sector

May boost sentiment for other pancreatic cancer and oncology biotech peers.

Regional

Limited to US biotech sector.

Global

Modest; primarily affects US‑listed biotech investors.

Counterpoint

What could challenge this read

If the data does not translate to regulatory approval, the rally could be short‑lived.

Key entities

  • company
    Verastem

    Biotech firm developing VS‑7375 for pancreatic cancer.

  • analyst
    BTIG

    Equity research firm issuing the Buy rating and price target.

Read at source← All news

Related articles

OCT 15
$VSTMHighAI 8/10

Mizuho raises Verastem stock price target on strong trial data

Mizuho raised its price target on Verastem Inc. (VSTM) to $14 from $13, citing strong clinical trial data for its oral KRAS G12D inhibitor. The stock trades at $7.71, with analysts' targets ranging from $12 to $24. Verastem plans a Phase 3 study and completed a $250 million financing. Multiple analysts maintain positive ratings, with price targets up to $19.

investing.com2 min
OCT 14
$VSTMHighAI 9/10

Verastem, Inc. entered into an underwriting agreement with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named…

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 14, 2026, Verastem, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named in Schedule I thereto (the “Un

SEC EDGAR 8-K2 min
OCT 14
$VSTMMedAI 9/10

Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III

Verastem (VSTM) reported positive results for its KRAS G12D drug in pancreatic, colorectal, and lung cancer trials. Key data includes a 43% response rate in lung cancer and 75% in frontline lung cancer combinations. The FDA agreed to the Phase III pancreatic cancer study design. The company expects to complete Phase II enrollments by year-end and has secured financing to fund operations into 2028.

finance.yahoo.com2 min